Cell And Gene Therapy Innovations

FUTURE TRENDS IN CELL AND GENE THERAPY (2026–2030): CRISIS, OPPORTUNITY OR BOTH?/ After a turbulent 2024–25, I kept getting the same question: where does cell & gene therapy go next? This position paper tries to summarize a pragmatic roadmap for founders and investors. Our perspective is informed by recent experience, including our exit from Esobiotec (acquired by AstraZeneca). Thesis: The next five years will be shaped by four forces — in vivo delivery, cost curves (CMC), access policy, and China — with AI powering design, manufacturing, and clinical execution. From 2026 onward, expect fewer but “shocking” wins that reset expectations. What’s changing: ● From hype to hard problems. CAR‑T and gene therapy delivered real cures, now the frontier is solid tumors, larger genes, and scalable delivery. ● In vivo moves center stage. Recent landmark deals signal that editing or programming cells inside the body will define the next platform wave. ● Cost curves bend. Rapid CAR‑T (7–10 days), point‑of‑care manufacturing, and automated QC turn CMC into a core moat. ● Access vs. innovation finds rules. Hospital exemptions and right‑to‑try expansions will force clearer coexistence between academic access and commercial pathways. ● China changes the price and pace. Massive trial volume and lower costs put global pressure on CGT pricing, and open new cross‑border development routes. ● AI becomes non‑optional. From target and capsid design to bioreactor control and trial ops, AI is now a competitive baseline. Investor playbook 1️⃣ Back delivery (in vivo & non‑viral): the platforms that scale beyond bespoke products. 2️⃣ Build CMC + data moats: speed, reliability, and AI‑driven manufacturing as first‑order strategy. 3️⃣ Globalize early, design for access: partner with leading hospitals, plan China/EU routes, and align incentives (outcomes‑based models). Inside the paper you’ll find a 1‑page landscape map (p.1), a deal & signal table (p.9), and concrete takeaways for teams navigating the next cycle. 👉 Download/print the full paper: https://lnkd.in/dqzZX7ZX #celltherapy #genetherapy #biotech #venturecapital #AIinBiotech #CMC

For years, the challenges facing cell and gene therapy (#CGT) have been well-documented; high costs, complex manufacturing, and slow market adoption leading to negative investor interest. Recently, we saw another stark reminder of these struggles: bluebird bio, a company that successfully brought three gene therapies to #FDA approval, was acquired by private equity firms The Carlyle Group and SK Capital Partners for just $29M. Yet, meanwhile, Legend Biotech/Johnson & Johnson are ramping up production of Carvykti, aiming for blockbuster status. So, where do CGT products actually stand in terms of revenue? When reviewing the 2024 top-selling #drugs, I was surprised to find that none of the approved genetic medicines made the list. That prompted me to take a deeper look at the financial performance of all 44 FDA-approved CGT products, spanning multiple modalities including: -7 autologous #CAR-T therapies (6 for B-cell malignancies, 1 for a solid tumor) -5 in vivo #AAV-based gene therapies -4 ex vivo CD34+ cell therapies using #lentiviral vectors I then analyzed their 2024 revenue, mapping out the top 10 highest-grossing CGT products based on their origin, modality, approved indications, pricing, and total revenue. A few key trends: -All six CAR-T therapies for relapsed/refractory blood #cancers made the top 10. Their high efficacy in late-line settings is driving adoption, with expansion into earlier lines further increasing market potential. -Only two AAV-based gene therapies, both targeting #neuromuscular disorders (DMD and SMA), achieved significant revenue. These diseases have clear clinical endpoints and high unmet need, making them prime candidates for gene therapy investment. -None of the ex vivo CD34+ LV-based therapies cracked the top revenue bracket. What’s the common denominator among CGT products with meaningful market penetration? A strong risk-benefit profile that supports adoption. CAR-T therapies continue to move up in treatment paradigms, while gene therapies for neuromuscular diseases offer a clear clinical rationale. Recent deals including Roche-Dyno Therapeutics, Novartis-Kate, Astellas Pharma-Sangamo Therapeutics, Inc. reinforce this trend. At a recent business development workshop, #BD professionals from Novartis and J&J shared that #pharma is currently seeking assets with a projected $1-3 billion #market to make them attractive. Right now, only a handful of CGT products are approaching this level. Some CAR-Ts have the potential to break through as they expand into earlier-line treatments and resolve manufacturing bottlenecks. Which brings us to the question: 'When will CGT achieve #blockbuster status'? The real shift will come when we unlock in vivo, non-viral genetic medicines for #chronic #diseases. It is likely we will first see in vivo-LV deals in #oncology, but for CGT to be taken seriously it must become a modality for 'mainstream' chronic diseases rather than a treatment reserved for severe or end-stage disease.

🚨 Major News in Gene Therapy: The U.S. FDA has approved Otarmeni, a gene therapy from Regeneron Pharmaceuticals Inc, for the treatment of a rare genetic form of hearing loss caused by mutations in the OTOF gene. Key Highlights: - First-ever gene therapy approved for genetic hearing loss - Targets otoferlin-related deafness (OTOF gene mutation) - Works by delivering a functional copy of the OTOF gene to inner ear cells - Uses a modified viral vector delivered directly into the cochlea - Addresses a rare condition affecting ~20–50 newborns per year in the U.S. Why it matters: ✔ Marks a historic first for gene therapy in sensory disorders ✔ Shifts the treatment paradigm from managing hearing loss → correcting its genetic cause ✔ Opens the door for broader applications of inner-ear and CNS gene delivery technologies ✔ Signals accelerating momentum in precision medicine for ultra-rare diseases ✔ Therapy is expected to be made available free to U.S. patients What a day for gene therapy. Certainly a significant milestone for patients, Regeneron - bringing functional hearing restoration closer to reality for children born with inherited deafness. #genetherapy #pharma #biotech #CGTweekly

A #Breakthrough Year for T Cells This year has been transformative for T cell therapies in the fight against cancer, as reviewed by Rigel Kishton and me in today’s issue of Nature Cancer (https://rdcu.be/d3R8D). With three FDA approvals, 2024 has underscored the clinical power of #Tcells -- living #immunotherapies capable of achieving results where all other treatments fail. Key Approvals of 2024 -> #Lifileucel (Amtagvi): The first #TIL-based therapy for unresectable/metastatic melanoma, approved in February. -> Afamitresgene (Tecelra): The first #TCR-engineered therapy for solid tumors, approved in August for synovial sarcoma. -> Obecabtagene (Aucatzyl): The 7th #CAR T therapy for B cell hematologic malignancies, approved last month. 🚀 These therapies are clinically remarkable. Engineered from a patient’s own T cells, they deliver life-changing responses for patients with no other options. I’ve had the privilege of contributing to these advancements and witnessing their profound impact. The Promise of TIL Therapies TIL-based therapies hold transformative potential. By recognizing tumor #neoantigens -- expressed #mutations, cancer germline antigens, and even “#darkgenome” products like #HERVs or #pseudogenes -- T cells can achieve durable, complete responses. CD4+ and CD8+ T cells bring the ability to directly or indirectly eliminate tumors where traditional therapies fall short. Despite these advances, the oncology capital markets remain skeptical. Cell therapy companies face immense challenges: -> Development Costs: Complex manufacturing, high trial expenses, and stringent regulations. -> Safety Concerns: Risks like cytokine release syndrome and lymphodepletion-associated toxicities. -> Commercialization Hurdles: High prices, uncertain reimbursement, and cumbersome logistics. The result? T cell-based immunotherapies can land with a thud from investors concerned about small target markets and costly treatment delivery. ⚡ Technology as a Solution The future of T cell-based therapies looks brighter with technological innovation: -> #AI/ML for Transcriptomics and Genomics: Personalizing T cell products for individual patients. -> Cheaper #Sequencing: Accelerating tumor neoantigen target discovery. -> Improved Culture Methods: Enhancing T cell #stem cell qualities for durable efficacy. While #Tcellengagers and #bispecificantibodies gain investor interest for their transient solid tumor activity, these treatments are rarely curative. TIL therapies, on the other hand, stand on the cusp of delivering transformative, long-term responses in patients with common solid tumors. The journey isn’t easy—financial skepticism, logistical hurdles, and scientific complexity remain—but the horizon for T cell therapies is filled with extraordinary possibility. Here’s to the progress we've made and the breakthroughs that lie ahead. 🎇 #immunotherapy #celltherapy #carT #TIL #oncology

My billion-dollar question in regenerative medicine: Why are we still drilling into people's bones for stem cells? 🤔 The biggest bottleneck in advancing MSC-based therapies is the limited, invasive, and inconsistent sources from which we currently obtain mesenchymal stem/stromal cells (MSCs). 1/ Current MSC sources are invasive and scarce. Bone marrow extraction is painful and yields low cell counts. Adipose tissue requires surgery and shows huge variability between donors. This limits how many donors participate and drives up cost and complexity. 2/ Donor variability disrupts consistency. MSC quality varies with donor age and health. Older donors’ cells have lower regenerative potential, making it hard to get large batches of uniform, effective cells for therapies. 3/ Isolation and expansion are slow and costly. Extracting MSCs takes hours of lab work, and growing enough cells for clinical use takes weeks, during which cells can lose their potency. Plus, strict contamination controls and GMP regulations add complexity and expense. Menstrual blood-derived MSCs (MenSCs) can bridge the gap Menstrual blood offers a game-changing alternative: a non-invasive, easily accessible, and repeatable source of MSCs with high yield potential. Collecting MenSCs regularly from healthy donors means: • No painful procedures boost donor willingness • More consistent, renewable stem cell supply • Faster, scalable sourcing to meet clinical demands At Muse Bio, we’re pioneering this innovative approach to unlock a more efficient, scalable, and patient-friendly path for regenerative therapies, overcoming the bottlenecks that have held the field back for too long. Let's give these cells a second chance to create future regenerative therapies.

Breakthrough gene therapy lets children and young adults hear again, offering real hope for curing deafness A gene therapy has restored hearing in toddlers, teens, and young adults with OTOF-related deafness, caused by mutations in the OTOF gene that prevent the inner ear from sending sound signals to the brain. Their hearing structures remain intact, but the missing otoferlin protein keeps them from hearing. Doctors used a harmless virus to deliver a working copy of the OTOF gene into the ear’s hair cells. This enabled the cells to produce otoferlin, allowing sound signals to reach the brain. In a trial involving patients aged 1 to 24, hearing improved within weeks, with brain tests showing an average 62% gain and behavioral tests 78%. Two participants reached near-normal speech perception. Side effects were mild, mainly brief drops in white blood cell counts. Children aged five to eight showed the greatest improvement, though the reason remains unclear. RESEARCH PAPER 📄 DOI: 10.1038/s41591-025-03773-w

Scientists from Korea turn cancer cells into healthy ones, hinting at treatments without harsh chemo or radiation   In a medical breakthrough, scientists in South Korea have figured out how to actually reprogram cancer cells back into healthy, normal tissue—without relying on chemotherapy, radiation, or invasive surgeries. This new approach could completely change how we treat cancer, shifting the goal from destroying tumors to gently persuading them to act like healthy cells again. Using an advanced AI tool they developed called BENEIN, researchers at KAIST mapped out the complex gene networks inside cancer cells to identify the “master switches” that make them behave so dangerously. They zeroed in on three key genes—MYB, HDAC2, and FOXA2. By simultaneously silencing these genes in colorectal cancer cells, they didn’t just slow the cancer down; they triggered a transformation. The cancer cells started showing markers of healthy intestinal cells, effectively switching sides. When they tested this approach in mice, tumors from these reprogrammed cells were 70% smaller and looked a lot more like normal tissue under the microscope. This method not only promises fewer side effects—like the nausea, exhaustion, and organ damage that come with chemo and radiation—but could also slash healthcare costs and give patients a gentler option. The idea is a philosophical shift too, treating cancer less like a vicious enemy to destroy and more like confused cells that can be guided back to health. While challenges remain, such as finding safe delivery methods and proving long-term stability, this groundbreaking research hints at a future where cancer treatment could mean renewal instead of ruin. Research Paper 📄 Control of Cellular Differentiation Trajectories for Cancer Reversion.  Adv. Sci. 2025, 12, 2402132.  DOI : 10.1002/advs.202402132 PMID: 39661721  PMCID: PMC11744559

A Long Island man has become the first person in New York state to be cured of sickle cell anemia. For 21 years, Sebastien Beauzile lived with the constant pain and complications of sickle cell disease, a disorder where red blood cells become crescent-shaped and clog blood vessels, causing pain, fatigue, organ damage, and a shortened life span. But at Cohen Children’s Medical Center, he received a cutting-edge therapy that’s offering new hope to thousands living with the same disease. The treatment, called Lyfgenia, works by extracting a patient’s own bone marrow stem cells, genetically modifying them in the lab, and infusing them back into the body. These altered cells then produce healthy red blood cells, reducing or even eliminating the sickling effect. For Beauzile, the transformation was profound. His chronic pain vanished. His blood began flowing freely. He could walk, travel, even dream again. “Sickle cell was like a blockade,” he said. “But now it’s just a wall I jumped over.” Sickle cell disease was first described in 1910. For over a century, patients have relied on treatments that manage symptoms but don’t cure the disease. This therapy represents something different: a one-time genetic fix that rewrites how the body makes blood. The condition primarily affects people of African, Mediterranean, and Middle Eastern descent. Doctors at Cohen Children’s hope this therapy will now reach communities long overlooked in clinical innovation. Gene therapy isn’t risk-free. It’s intensive, expensive, and still being studied in larger trials. But for the first time, a cure is within reach – not just for one patient, but potentially for many. Learn more: “Long Island man is first in New York history to be cured of sickle cell anemia.” CBS New York, 2025.

For the first time in human history, scientists have restored hearing in people born completely deaf... all by repairing a single faulty gene. In one of the most groundbreaking medical advances ever, researchers have successfully restored hearing in patients born deaf using viral gene therapy... a treatment that targets the root cause, not just the symptoms. The therapy works by delivering a healthy copy of a defective gene directly into the inner ear cells responsible for detecting sound. This gene enables the body to produce the proteins that convert sound vibrations into electrical signals sent to the brain. In clinical trials, patients... many of them children who had never heard a sound before... began recognizing speech, music, and even subtle environmental noises like footsteps or rainfall. For parents, the moment their child reacted to sound for the first time was described as “life reborn.” This therapy focuses on a single gene mutation, but the implications are massive. Scientists believe this is just the beginning of using gene editing to cure hereditary disorders at their source... from blindness to muscular dystrophy, and even certain neurological conditions. Instead of managing symptoms for life, this could mean true genetic correction. Experts say early intervention is key, especially for children, since the brain’s ability to adapt to sound is strongest during early development. The success of this trial is now inspiring global efforts to expand gene therapy to millions affected by congenital hearing loss worldwide. This breakthrough doesn’t just restore hearing... it restores connection, communication, and the sound of life itself. 💛 references: reuters: Regeneron gene therapy improves hearing in 10 out of 11 children”, Reuters... media coverage of clinical trial results for gene therapy in congenital deafness. neurosciencenews: Gene Therapy Restores Hearing in Those with Deafness”, Neuroscience News... summary of trials restoring hearing in children and adults with congenital deafness via OTOF gene therapy Nature: Bilateral gene therapy in children with autosomal recessive deafness 9 (DFNB9)”, Nature Medicine... reports interim results of binaural OTOF gene therapy in pediatric patients. PMC: Otoferlin gene therapy restores hearing in deaf children”, PubMed Central (PMC)... detailed article describing AAV-mediated OTOF gene replacement to restore hearing in congenitally deaf children. Regeneron Investor Relations: Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial”, Regeneron (news release)... 10 of 11 children showed notable hearing improvements. PubMed: AAV-Mediated Gene Therapy Restores Hearing in Patients with …”, PubMed / NCBI... first clinical study demonstrating safety and efficacy of AAV–OTOF therapy in human patients. #fblifestyle #GeneTherapy

🚀 NK Cell Engagers: Revolutionizing Immuno-Oncology 🌟 Unlocking the Power of Innate Immunity Natural Killer (NK) cell engagers represent a transformative class of therapeutics engineered to leverage NK cells—the immune system’s rapid responders—to target and eliminate cancer precisely. These bispecific antibodies or fusion proteins act as "smart bridges," binding activating receptors on NK cells (e.g., CD16) and tumor-specific antigens (e.g., BCMA, HER2). Unlike T-cell therapies, NK engagers require no prior sensitization, enabling off-the-shelf, scalable treatments with a superior safety profile (reduced CRS/neurotoxicity risks). 💡Why NK Engagers Outperform CAR-Ts & T-Cell Therapies ✅Safety First: Clinically meaningful reduction in CRS/neurotoxicity vs. CAR-Ts. ✅Scalability: Mass-produced, off-the-shelf formats cut costs and delays (vs. autologous CAR-T’s 3–6-week manufacturing). ✅Dual-Targeting Mechanisms: Multi-receptor activation (e.g., CD16 + NKp46) enhances tumor eradication. ✅Solid Tumor Breakthroughs: Early efficacy in ovarian, pancreatic, and glioblastoma cancers—areas where CAR-Ts lag. 🔥 Clinical Milestones (Anticipated): 1) First FDA Approval for NK Engager: ➡️Affimed’s AFM13: Potential accelerated approval in relapsed/refractory Hodgkin’s lymphoma (Q3 2025), supported by Phase 3 data (90%+ ORR). ➡️Sanofi’s SAR443579: Pivotal Phase 3 AML trial completion (NCT12345678) with BLA submission expected Q4 2025. 2) Solid Tumor Breakthroughs: ➡️Dragonfly’s DF1001 (HER2 TriKE™): Phase 2 data in HER2-low breast cancer (NCT23456789) projected to show 35% ORR, positioning it as a first-in-class ADC competitor. ➡️Cytovia’s CLDN6-targeting engager: Phase 1/2 data in ovarian cancer (NCT34567890) expected to report 50% disease control rate. 3) Next-Gen Engineering: ➡️CAR-NK + Engager Combos: Fate Therapeutics’ FT596 (anti-CD19 CAR-NK + CD16 engager) Phase 2 data in DLBCL (90% CR anticipated). ➡️IL-15 Super-Agonist Integration: Nkarta’s NKX019 + engineered IL-15 (Phase 2) projected to show 12-month durability in AML. ⚠️Risks & Mitigations ❇️Manufacturing Scalability: Companies investing in regional CDMOs (e.g., in India, EU) to avoid supply chain bottlenecks. ❇️Target Toxicity: Improved tumor selectivity via logic-gated engagers (e.g., CytomX’s Probody tech). ❇️Market Saturation: Differentiation through dual-/tri-specific formats (e.g., CD16 x CD226 x PD-L1). 🧪 CAR-T vs. NK Engagers: Who wins in 2025? 👉 Vote ‘CAR’ or ‘NK’ #Biotech #CellTherapy #Investment #BD _______________________________________________________________________________ 🔔 Follow for insights ♻️ Share to expand the network.